SEARCH

SEARCH BY CITATION

References

  • Banwait, R., O'Regan, K., Campigotto, F., Harris, B., Yarar, D., Bagshaw, M., Leleu, X., Leduc, R., Ramaiya, N., Weller, E. & Ghobrial, I.M. (2011) The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. American Journal of Hematology, 86, 567572.
  • Barakat, F.H., Medeiros, L.J., Wei, E.X., Konoplev, S., Lin, P. & Jorgensen, J.L. (2011) Residual monotypic plasma cells in patients with Waldenstrom macroglobulinemia after therapy. American Journal of Clinical Pathology, 135, 365373.
  • Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. & Eisenhauer, E. (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 15701575.
  • Del Giudice, I., Matutes, E., Osuji, N., Parry-Jones, N., Swansbury, J. & Catovsky, D. (2005) Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. Haematologica, 90, 268270.
  • García-Sanz, R., Ocio, E., Caballero, A., Magalhães, R.J.P., Alonso, J., López-Anglada, L., Villaescusa, T., Puig, N., Hernández, J.M., Fernández-Calvo, J., Aguilar, A., Martín, A., López, R., Paiva, B., Orfao, A., Vidriales, B., San-Miguel, J.F. & Del Carpio, D. (2011) Post-treatment bone marrow residual disease >5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 168171.
  • Gertz, M.A., Abonour, R., Heffner, L.T., Greipp, P.R., Uno, H. & Rajkumar, S.V. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology, 147, 677680.
  • Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 54465456.
  • Itzykson, R., Le Garff-Tavernier, M., Katsahian, S., Diemert, M.-C., Musset, L. & Leblond, V. (2008) Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica, 93, 793794.
  • Katzmann, J.A., Snyder, M.R., Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Benson, J.T. & Dispenzieri, A. (2011) Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clinical Chemistry, 57, 16871692.
  • Kimby, E., Treon, S.P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.-P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M. & Bladé, J. (2006) Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clinical Lymphoma & Myeloma, 6, 380383.
  • Laszlo, D., Andreola, G., Rigacci, L., Fabbri, A., Rabascio, C., Mancuso, P., Pruneri, G., Radice, D., Pinto, A., Frigeri, F., Calabrese, L., Billio, A., Bertolini, F. & Martinelli, G. (2010) Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 22332238.
  • Leleu, X., Moreau, A.-S., Weller, E., Roccaro, A.M., Coiteux, V., Manning, R., Nelson, M., Leduc, R., Robu, D., Dupire, S., Hatjiharissi, E., Burwick, N., Darre, S., Hennache, B., Treon, S.P., Facon, T., Gertz, M.A. & Ghobrial, I.M. (2008) Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leukemia & Lymphoma, 49, 11041107.
  • Leleu, X., Xie, W., Bagshaw, M., Banwait, R., Leduc, R., Roper, N., Weller, E. & Ghobrial, I.M. (2011a) The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17, 30133018.
  • Leleu, X., Koulieris, E., Maltezas, D., Itzykson, R., Xie, W., Manier, S., Dulery, R., Boyle, E., Gauthier, J., Poulain, S., Tatiana, T., Panayiotidis, P., Bradwell, A.R., Harding, S., Leblond, V., Kyrtsonis, M.-C. & Ghobrial, I.M. (2011b) Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 164167.
  • Manier, S., Lejeune, J., Musset, L., Boyle, E., Dulery, R., Debarri, H., Faucompret, J.-L., Gauthier, J., Bories, C., Fouquet, G., Herbaux, C., Tricot, S., Pietrantuono, A., Combat, F., Poulain, S., Harding, S., Leblond, V. & Leleu, X. (2011) Hevylite, a novel M-component based biomarkers of response to therapy and survival in Waldenstrom macroglobulinemia. Blood (ASH Annual Meeting Abstracts), 118, 2667.
  • Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M.B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. & Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 29712979.
  • Morice, W.G., Chen, D., Kurtin, P.J., Hanson, C.A. & McPhail, E.D. (2009) Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Modern pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 22, 807816.
  • Murray, D.L., Ryu, E., Snyder, M.R. & Katzmann, J.A. (2009) Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clinical Chemistry, 55, 15231529.
  • Owen, R.G., Barrans, S.L., Richards, S.J., O'Connor, S.J., Child, J.A., Parapia, L.A., Morgan, G.J. & Jack, A.S. (2001) Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. American Journal of Clinical Pathology, 116, 420428.
  • Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 110115.
  • Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J.J., Montalbán, M.A., Sureda, A., Montejano, L., Gutiérrez, N.C., García de Coca, A., de Las Heras, N., Mateos, M.V., López-Berges, M.C., García-Boyero, R., Galende, J., Hernández, J., Palomera, L., Carrera, D., Martinez, R., de la Rubia, J., Martin, A., Blade, J., Lahuerta, J.J., Orfao, A. & San Miguel, J.F. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 112, 40174023.
  • Pasricha, S.-R., Juneja, S.K., Westerman, D.A. & Came, N.A. (2011) Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. Journal of Clinical Pathology, 64, 520523.
  • Rajkumar, S.V., Harousseau, J.-L., Durie, B., Anderson, K.C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., Jagannath, S., Facon, T., Avet-Loiseau, H., Lonial, S., Palumbo, A., Zonder, J., Ludwig, H., Vesole, D., Sezer, O., Munshi, N.C. & San Miguel, J. (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 117, 46914695.
  • Rawstron, A.C., Davies, F.E., DasGupta, R., Ashcroft, A.J., Patmore, R., Drayson, M.T., Owen, R.G., Jack, A.S., Child, J.A. & Morgan, G.J. (2002) Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood, 100, 30953100.
  • Riches, P.G., Sheldon, J., Smith, A.M. & Hobbs, J.R. (1991) Overestimation of monoclonal immunoglobulin by immunochemical methods. Annals of clinical biochemistry, 28(Pt 3) 253259.
  • Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, France.
  • Tedeschi, A., Benevolo, G., Varettoni, M., Battista, M.L., Zinzani, P.L., Visco, C., Meneghini, V., Pioltelli, P., Sacchi, S., Ricci, F., Nichelatti, M., Zaja, F., Lazzarino, M., Vitolo, U. & Morra, E. (2012) Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer, 118, 434443.
  • Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A.I., Clark, B., Lucas, M.S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K.C. & Byrd, J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy (Hagerstown, Md.: 1997), 24, 272279.
  • Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B.R., Sharon, D., Steiss, R., Leleu, X., Branagan, A.R. & Badros, A. (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 13, 33203325.
  • Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J., 2nd,Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009) Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 38303835.
  • Treon, S.P., Tripsas, C.K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., Eradat, H., Gregory, S.A., Thomas, S., Advani, R., Baz, R., Badros, A.Z., Matous, J., Anderson, K.C. & Ghobrial, I.M. (2011a) Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia. Blood (ASH Annual Meeting Abstracts), 118, 2951.
  • Treon, S.P., Yang, G., Hanzis, C., Ioakimidis, L., Verselis, S.J., Fox, E.A., Xu, L., Hunter, Z.R., Tseng, H., Manning, R.J., Patterson, C.J., Sheehy, P. & Turnbull, B. (2011b) Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. British Journal of Haematology, 154, 223228.
  • Tripsas, C., Ioakimidis, L.I., Hunter, Z.R., Patterson, C.J., Manning, R.J., Sheehy, P.S., Turnbull, B. & Treon, S.P. (2012) Comparative response assessment by total serum IgM and IgM M-component in Waldenstrom's macroglobulinemia. Journal of Clinical Oncology, 30, e18575.
  • Varghese, A.M., Rawstron, A.C., Ashcroft, A.J., Moreton, P. & Owen, R.G. (2009) Assessment of bone marrow response in Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma, 9, 5355.
  • Weber, D., Treon, S.P., Emmanouilides, C., Branagan, A.R., Byrd, J.C., Bladé, J. & Kimby, E. (2003) Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 127131.